Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Targovax ASA ( (GB:0RIS) ) is now available.
Circio Holding ASA has reported that its rights issue of NOK 50 million was oversubscribed by more than 50%, prompting a parallel private placement of about NOK 15 million to cover all pre-subscriptions, bringing total gross proceeds to roughly NOK 65 million. The capital raise, strongly backed by long-term shareholders and company insiders, is expected to leave Circio in a stronger financial position, securing funding well into 2027 and enabling the company to accelerate development of its circVec circular RNA platform, expand its scientific team in Stockholm, and advance both partnering efforts and in-house gene and cell therapy programs, thereby reinforcing its ambition to become a leading player in circRNA-based gene expression technology.
More about Targovax ASA
Circio Holding ASA is a Norwegian biotechnology company focused on developing novel circular RNA (circRNA) expression technology for gene and cell therapies. Its proprietary circVec platform is a modular genetic construct designed to produce multifunctional circRNA inside target cells, delivering markedly extended RNA half-life and significantly enhanced protein expression compared with conventional mRNA-based viral and non-viral vectors. The technology is being advanced through its Stockholm-based subsidiary Circio AB and targets multiple therapeutic areas, while the company also continues a legacy immuno-oncology program, TG01, for RAS-mutated cancers via external clinical collaborations in Norway and the United States.
Average Trading Volume: 3,883,209
Current Market Cap: NOK204.9M
See more insights into 0RIS stock on TipRanks’ Stock Analysis page.